Marcus D. Goncalves, MD, PhD, shares details about this presentation, which begins Tuesday, June 29, at 9:30 a.m. ET.
Amir Moheet, MBBS, shares details about this presentation, which begins Friday, June 25, at 1:15 p.m. ET.
A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin.
Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.
Richard I.G. Holt, PhD, FRCP, and Anne L. Peters, MD, and their writing team will summarize the key topics addressed by this trans-Atlantic collaboration.
Veterans and active-duty military personnel with diabetes can now receive self-management education in a simulated environment.
Makoto Fukuda, PhD, and Tune H. Pers, PhD, will discuss GIP signaling in the brain and its effects on food intake and energy balance at this year’s ADA Diabetes Symposium.
In 1921, the discovery of insulin transformed type 1 diabetes from a death sentence. Peter Arvan, MD, PhD, and Michael A. Weiss, MD, PhD, MBA, will explore the ramifications of this critical inflection point in medicine.
Maisa N. Feghali, MD, Randi Streisand, PhD, CDCES, and Jessica Pierce, PhD, will outline how the strategies providers use to promote positive mental health for their patients living with diabetes must evolve as their patients mature.
David McIntyre, MD, FRACP, and Noelia M. Zork, MD, will discuss the perfect storm created by the confluence of COVID-19, diabetes, and pregnancy—from new approaches to the diagnosis and management of diabetes in pregnancy to an expansion of telemedicine.